Why the study?
Does intravenous disopyramide phosphate reduce ventricular ectopic beats and what are its hemodynamic effects in patients with persistent VEBs?
Does intravenous disopyramide phosphate reduce ventricular ectopic beats and what are its hemodynamic effects in patients with persistent VEBs?
Intravenous disopyramide effectively suppresses ventricular ectopic beats but causes significant negative inotropic effects, particularly in patients with elevated baseline diastolic pulmonary artery pressure.
Answers are grounded in this paper and cite their sources.
Alerts to hemodynamic risks with disopyramide in ventricular ectopy; leaves open its role pending higher-level evidence.
Antiarrhythmic and hemodynamic effects of i.v. disopyramide phosphate (1.7 mg/kg b.wt. over 2 min) have been studied in nine patients, several in various degrees of cardiac decompensation, with sinus rhythm and persistent ventricular ectopic beats (VEBs). In one case with primary cardiomyopathy, with greater than 30 VEBs/min, disopyramide (DE) abolished the arrhythmia for 30 min, but precipitated brief dysponea. Other side-effects were tolerable and mainly attributable to anticholinergic effects of the drug. DE either abolished or significantly reduced the arrhythmia in all cases. For 30 min, only one patient showed VEBs, and in three patients no VEBs were seen for three hours. Changes in cardiac output and pulmonary artery (PAP) and central aortic pressures were measured in eight patients. Negative inotropic effects were indicated in seven by an increased diastolic PAP/stroke volume ratio and in seven by a decreased central aortic (dp/dt)max. Patients with high control values for diastolic PAP showed marked reductions in cardiac output, stroke volume and stroke work. In predicting myocardial depressant effects of DE, the control values for diastolic PAP seemed to be superior to central venous pressure, cardiac index and systolic time intervals. Mean arterial pressure measured 5 and 10 min after drug administration showed no significant change, indicating that vasoconstrictor reflexes were well preserved, and a pressure level significantly above the control value was reached from the 20th min. It is concluded that DE is potent in suppressing VEBs but exerts negative inotropic effects that may be of clinical importance. The optimal antiarrhythmic dose is probably lower than that used in the present study.
No takes yet. Share an insight, caveat, or question.
Hulting et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: